RT Journal Article
SR Electronic
T1 Anti-Spike protein assays to determine post-vaccination antibody levels: a head-to-head comparison of five quantitative assays
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.05.21252977
DO 10.1101/2021.03.05.21252977
A1 Perkmann, Thomas
A1 Perkmann-Nagele, Nicole
A1 Koller, Thomas
A1 Mucher, Patrick
A1 Radakovics, Astrid
A1 Marculescu, Rodrig
A1 Wolzt, Michael
A1 Wagner, Oswald F.
A1 Binder, Christoph J.
A1 Haslacher, Helmuth
YR 2021
UL http://medrxiv.org/content/early/2021/03/08/2021.03.05.21252977.abstract
AB Background Reliable quantification of the antibody response to SARS-CoV-2 vaccination is highly relevant for identifying possible vaccine failure and estimating the time of protection. Therefore, we aimed to evaluate the performance of five different Anti-SARS-CoV-2 antibody assays regarding the quantification of anti-spike (S) antibodies induced after a single dose of BNT162b2.Methods Sera of n=69 SARS-CoV-2 naïve individuals 21±1 days after vaccination with BNT162b2 (Pfizer/BioNTech) were tested using the following quantitative SARS-CoV-2 antibody assays: Roche S total antibody, DiaSorin trimeric spike IgG, DiaSorin S1/S2 IgG, Abbott II IgG, and Serion/Virion IgG. Test agreement was assessed by Passing-Bablok regression. Results were further compared to the percent inhibition calculated from a surrogate virus neutralization test (sVNT) by correlation and ROC (receiver-operating-characteristics) analysis.Results Individual values were distributed over several orders of magnitude for all assays evaluated. Although the assays were in good overall agreement (ρ=0.80-0.94), Passing-Bablok regression revealed systematic and proportional differences, which could not be eliminated by converting the results to BAU/mL as suggested by the manufacturers. 7 (10%) individuals had a negative sVNT results (i.e. <30% inhibition). These samples were reliably identified by most assays and yielded low binding antibody levels (ROC-AUCs 0.84-0.93).Conclusions Although all assays evaluated showed good correlation, readings from different assays were not interchangeable, even when converted to BAU/mL using the WHO international standard for SARS-CoV-2 immunoglobulin. This highlights the need for further standardization of SARS-CoV-2 serology.Competing Interest StatementNP received a travel grant from DiaSorin. The Dept. of Laboratory Medicine received compensations for advertisement on scientific symposia from Roche, DiaSorin and Abbott, and holds a grant for evaluating an in-vitro diagnostic device from Roche. The GenScript sVNT test kit and the Serion IgG kit were kindly provided by the respective supplier (medac GmbH and DiaChrom), the Abbott S IgG kit and the DiaSorin TriS IgG kit were kindly provided by the manufacturers.Funding StatementThe GenScript sVNT test kit and the Serion IgG kit were kindly provided by the respective supplier (medac GmbH and DiaChrom), the Abbott S IgG kit and the DiaSorin TriS IgG kit were kindly provided by the manufacturers. There was no additional funding received for the present work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the Ethics Committee of the Medical University of Vienna (EK1066/2021). All participants provided written informed consent to donate blood for the evaluation of diagnostic test systems (EK404/2012).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available to interested researchers upon request from the corresponding author.SARS-CoV-2Severe acute respiratory syndrome Coronavirus 2COVID-19Coronavirus Disease 19NCNucleocapsidSSpike proteintAbtotal antibodyECLIAelectrochemiluminescence immunoassayRBDreceptor binding domainCMIAchemiluminescence microparticle assayCLIAchemiluminescence immunoassayELISAenzyme-linked immunosorbent assayBAU/Mlbinding antibody units per millilitersVNTsurrogate virus neutralization testROC-AUCreceiver-operating-charateristics area under the curve